Natera | Transforming Management of Genetic Disease.

IN THE NEWS

Joint Guideline from ACOG and SMFM Supports use of Non-Invasive Prenatal Testing (NIPT) for all Pregnant Women

IN THE NEWS

New Publication in Nature Cancer Demonstrates Signatera’s Ability to Evaluate Tumor Response to Immunotherapy


 

Personalizing cancer
care management

Custom-built testing for each cancer patient, to detect molecular residual disease (MRD) and help guide treatment decisions.

 

Learn more: Oncology

 

Assessing the health
of transplant patients

The most precise cell-free DNA (cfDNA) testing in organ health—developed from our trusted legacy.

 

Learn more: Organ Health

 

Informing women's health decisions

Women’s health testing for every phase of life—from planning a family and checking baby’s health to assessing risk for hereditary cancer.

 

Learn more: Women's Health


OUR CLINICAL EXPERTS

Connect with a genetic counselor remotely in your home or office

Learn More


IN THE NEWS

Panorama NIPT achieves 2 million test milestone.

Learn More


OUR TECHNOLOGY

Natera's core technology and finely tuned workflows cut through the noise to deliver superior clinical and analytical performance.

Learn More